Delivery Order SPE2DB22D1106-SPE2DB24FFCE4

Award Date 7/16/24
Potential Completion Date 7/17/24
Potential Value $40K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Defense Logistics Agency (DLA) awarded a $36,109.94 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of the ROTARIX VACCINE ORAL SYRINGE 1.5ML. This delivery order was issued under a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999 that AmerisourceBergen holds with DLA Troop Support Medical for delivering a comprehensive range of medical commodities to support military treatment programs and facilities worldwide. The contract does not have a...
The U.S. Defense Logistics Agency (DLA) awarded a $8,319.61 firm fixed-price delivery order contract to AmerisourceBergen Drug Corp, Corporate Office Division, for the supply of 4,565,177,734 units of the ROTARIX vaccine oral syringes (1.5 ml). This contract has an ultimate completion date of July 18, 2024. AmerisourceBergen, a major pharmaceutical distributor, has been awarded multiple Indefinite Delivery Contracts (IDCs) from the DLA and the Department of Justice Federal Bureau of...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 4,563,184,840 units of the ROTARIX vaccine oral syringes with a capacity of 1.5 ml. The $19,616.40 delivery order has a completion date of December 28, 2023 and was issued on December 27, 2023. Amerisourcebergen Drug Corp, headquartered in Conshohocken, Pennsylvania, has previously received numerous federal contract awards...
The U.S. Defense Logistics Agency (DLA) has awarded Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a firm fixed price delivery order contract valued at $10,268.58 for the provision of ROTARIX vaccine oral syringes. The award has a completion date of February 22, 2024. Amerisourcebergen Drug Corp is the prime contractor, and this order is fulfilled under an existing indefinite delivery contract (IDC) between DLA and Amerisourcebergen Drug Corp valued at up to...
The Defense Logistics Agency has awarded a firm fixed price delivery order worth $7,880.13 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the provision of ROTARIX VACCINE ORAL SYRINGE 1.5ML. This order is part of a larger indefinite delivery contract (IDC) worth up to $999,999,999.00 that Amerisourcebergen Drug Corp holds with DLA, which serves as the primary contract vehicle for the company to deliver pharmaceutical products and medical supplies to DLA...
This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a subsidiary of the global pharmaceutical distributor AmerisourceBergen Corporation. The $28,024.98 order is for the supply of the ROTARIX vaccine oral syringes (1.5 mL) to support military treatment programs and facilities. AmerisourceBergen Drug Corp holds an indefinite delivery contract (IDC) with DLA, valued up to $999,999,999.00 through December 31, 2025, which serves as...
The Defense Logistics Agency (DLA) awarded Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a $15,494.25 firm fixed price delivery order contract to provide Rotarix vaccine oral syringes (1.5 mL). This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp, with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as the primary contract vehicle for...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order valued at $2,175.45 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of 1.5ml Rotarix vaccine oral syringes. This delivery order was issued under an existing indefinite delivery contract (IDC) held by Amerisourcebergen Drug Corp, valued at up to $999,999,999.00 and with a performance period through December 31, 2025. The IDC serves as the primary contract vehicle for...
The U.S. Defense Logistics Agency (DLA) awarded a $3,661.95 firm-fixed-price delivery order to AmerisourceBergen Drug Corp's Corporate Office division. The order is for the supply of 4,565,735,107 units of the ROTARIX vaccine oral syringes, 1.5 mL size. The contract has a completion date of September 10, 2024 and is not designated as a set-aside. AmerisourceBergen, a major pharmaceutical distributor, has been awarded numerous federal contracts and Indefinite Delivery Contracts (IDCs) by...
The U.S. government's Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of the pharmaceutical distribution company Amerisourcebergen Corporation. The $31,039.34 contract is for the supply of the ROTARIX vaccine oral syringes for the DLA Troop Support Medical program. This award is part of a larger indefinite delivery contract (IDC) valued up to $999,999,999.00, which serves as the primary vehicle for Amerisourcebergen...
  • SPE2DB22D1106
    Indefinite Delivery Contract
  • SPE2DB22D1106-SPE2DB24FFCE4
    Delivery Order

The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order worth $40,202.40 to AmerisourceBergen Drug Corporation's Corporate Office division. The order is for 4,565,161,303 units of the ROTARIX vaccine oral syringe, 1.5 mL. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between DLA Troop Support Medical and AmerisourceBergen, valued at up to $999,999,999 through December 2025, for providing a comprehensive range of pharmaceutical and medical supplies to support military treatment programs and facilities worldwide. The contract has a performance period through July 17, 2024 and did not utilize a set-aside designation.

Generated 10/15/24, 9:34 PM